New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

− Early proof of concept study showed TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo

− A second Phase 1 study in healthy sleep-deprived adults demonstrated that TAK-925 was well tolerated and increased wakefulness at night compared to placebo

− TAK-994, an oral selective OX2R agonist, reduced narcolepsy symptoms in narcolepsy mouse models and is progressing in Phase 1 studies

• In a Phase 3 study, SB8 demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR) to reference bevacizumab AVASTIN® i in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
• Safety, pharmacokinetics, and immunogenicity were also comparable
• Marketing authorization application for SB8 accepted for review by the European Medicines Agency (EMA)

INCHEON, Korea-Friday 27 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).ii The study results will be presented for the first time today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

“Data from this stu ... Read more »

HOUSTON-Friday 27 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Ascend Performance Materials has received permit approval from the Alabama Department of Environmental Management for its previously announced adiponitrile capacity expansion and the installation of a cogeneration unit at its Decatur facility.

“Our unique ADN technology allows us to bring on additional capacity in a timely and cost-effective manner to meet our commitment to supporting customer growth,” said Phil McDivitt, Ascend’s president and CEO. “Installing a cogen unit will enable us to meet our commitment to more sustainable operations.”

The company estimates that the cogeneration unit will reduce greenhouse gas emissions at its Decatur facility by 60 percent. Both the ADN expansion and the cogeneration unit installation will occur in phases over the next 24 to 36 months.

About Ascend Performance Materials

Ascend Performance Materials is a glo ... Read more »